SPIRE I & II

THIS STUDY EVALUATED THE PCSK9 INHIBITOR, BOCOCIZUMAB (PF04950615;RN316), COMPARED TO PLACEBO, IN REDUCING THE OCCURRENCE OF MAJOR cardiovascular EVENTS:

  • Cardiovascular Death

  • Myocardial Infarction

  • Stroke

  • Unstable Angina Requiring Urgent Revascularization

The study was performed in high risk subjects who were receiving background lipid lowering therapy and specific cholesterol laboratory values.

 

SPIRE Metrics - Argentina

  • Sites Initiated: 50

  • Sites Randomized: 46

  • Patients Screened: 1,038

  • Patients Randomized: 517